UnitedHealth's stock price has dropped about 17% to $259, falling below the price at which Berkshire Hathaway bought 5 million shares in Q2 2025, valued initially at $1.57 billion. The decline reflects rising medical costs, regulatory investigations into Medicare fraud, and repeated earnings misses, which have erased over a third of the company's market value this year. Berkshire's purchase marks its first major stake in UnitedHealth since 2010, signaling a contrarian bet despite the company's ongoing challenges. The stock remains under pressure as UnitedHealth navigates higher expenses and legal scrutiny.
UnitedHealth Group reported a strong second-quarter net income of $5.48 billion, driven by a significant reduction in medical costs. The company lowered its medical care ratio to 86.7% from 89.4% year-over-year by exiting unprofitable markets and man...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
